NMT Reassures GenMark Following Luminex Deal; GenMark Continuing Diligence | GenomeWeb

NEW YORK (GenomeWeb News) – While GenMark Diagnostics continues to seek clarification around the consequences of Luminex's collaboration and licensing deal with Natural Molecular Testing, GenMark officials said that it appears that the deal is independent of its own contract with NMT, and NMT is not looking to switch platforms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.